Quantum Computing Market in Drug Discovery: Distribution by Drug Discovery Service Offered (Target Identification / Validation, Hit Generation / Lead Identification and Lead Optimization), Therapeutic Area (Cardiovascular Disorders, CNS Disorders, Dermatological Disorders, Endocrine Disorders, Gastrointestinal Disorders, Immunological Disorders, Infectious Diseases, Musculoskeletal Disorders, Oncological Disorders, Respiratory Disorders and Others), and Key Geographical Regions (North America (US and Canada), Europe (UK, France, Germany and Rest of the Europe), Asia-Pacific (China, Japan and Rest of the Asia Pacific), Latin America and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035
The quantum computing in drug discovery services market is expected to reach USD 411 million in 2022 anticipated to grow at a CAGR of 16% during the forecast period 2022-2035.
During the early stages of drug development, the identification of a pertinent biological target and a promising lead compound plays a pivotal role in determining the subsequent success of a drug candidate throughout preclinical and clinical studies. The journey from the inception of a pharmacological lead to the eventual market launch spans approximately 10 to 15 years and requires substantial financial investments ranging from USD 4 billion to USD 10 billion. Notably, the complexities associated with drug discovery have intensified, particularly concerning large molecules, which inherently possess greater intricacies compared to their smaller counterparts.
To overcome the inherent challenges in drug discovery, such as escalating capital requirements and high attrition rates in late-stage programs, numerous pharmaceutical entities are currently exploring the integration of quantum computing into their discovery processes. Quantum computing leverages the principles of quantum mechanics to solve extensive and intricate problems within considerably shortened time frames compared to conventional computer-aided drug discovery methods.
Presently, various quantum computing approaches are employed in the realm of drug discovery, encompassing methodologies like structure-based drug design, fragment-based drug discovery, and ligand-based drug discovery. The predictive capabilities inherent in quantum computing have demonstrated a notable reduction in complexity, costs, and time investments throughout the entire drug discovery continuum. This breakthrough allows researchers to circumvent the laborious task of randomly screening billions of molecules, thereby significantly expediting the process.
Consequently, stakeholders in the pharmaceutical industry are increasingly relying on companies offering quantum computing software and hardware to bolster their drug discovery endeavors. Moreover, given the active initiatives undertaken by quantum computing entities, there exists a strong conviction that the prospects within this nascent, yet burgeoning industry segment will steadily expand in the foreseeable future.
Report Coverage
During the early stages of drug development, the identification of a pertinent biological target and a promising lead compound plays a pivotal role in determining the subsequent success of a drug candidate throughout preclinical and clinical studies. The journey from the inception of a pharmacological lead to the eventual market launch spans approximately 10 to 15 years and requires substantial financial investments ranging from USD 4 billion to USD 10 billion. Notably, the complexities associated with drug discovery have intensified, particularly concerning large molecules, which inherently possess greater intricacies compared to their smaller counterparts.
To overcome the inherent challenges in drug discovery, such as escalating capital requirements and high attrition rates in late-stage programs, numerous pharmaceutical entities are currently exploring the integration of quantum computing into their discovery processes. Quantum computing leverages the principles of quantum mechanics to solve extensive and intricate problems within considerably shortened time frames compared to conventional computer-aided drug discovery methods.
Presently, various quantum computing approaches are employed in the realm of drug discovery, encompassing methodologies like structure-based drug design, fragment-based drug discovery, and ligand-based drug discovery. The predictive capabilities inherent in quantum computing have demonstrated a notable reduction in complexity, costs, and time investments throughout the entire drug discovery continuum. This breakthrough allows researchers to circumvent the laborious task of randomly screening billions of molecules, thereby significantly expediting the process.
Consequently, stakeholders in the pharmaceutical industry are increasingly relying on companies offering quantum computing software and hardware to bolster their drug discovery endeavors. Moreover, given the active initiatives undertaken by quantum computing entities, there exists a strong conviction that the prospects within this nascent, yet burgeoning industry segment will steadily expand in the foreseeable future.
Report Coverage
- An executive summary of the key insights captured in our report. It offers a high-level view of the current scenario of quantum computing in drug discovery services market and its likely evolution in the short term to mid-term and long term.
- Overview of quantum computing, along with information on its business and platform capabilities with respect to its use across various industries Additionally, it highlights the application of quantum computing, specifically in drug discovery. Further, the chapter features a discussion on the challenges, key growth drivers, and future perspectives associated with the use of quantum computing in drug discovery services.
- A detailed assessment of the overall market landscape of quantum computing software providers, based on several relevant parameters including year of establishment, company size, location of headquarters, business capabilities, platform capabilities, type of drug discovery service(s) offered, type of molecule(s) supported, compatible computational approaches, end user(s) and therapeutic area(s)
- An insightful company competitiveness analysis of quantum computing service providers based on company strength (in terms of the years of experience), portfolio strength (in terms of type of drug discovery services offered, type of molecule(s) supported, type of computational approaches and type of end-user(s)), and portfolio diversity (in terms of business capabilities).
- Elaborated profiles of quantum computing software providers . Each profile includes a brief overview of the company, financial information (if available), details on service portfolio, recent developments and an informed future outlook.
- A detailed assessment of the overall market of quantum computing hardware providers based on various parameters including year of establishment, company size, location of headquarters, type of offering(s), data storage on cloud and compatible computational approaches.
- Detailed profiles of quantum computing hardware providers. It includes a brief overview of the company, financial information (if available), details of service portfolio, recent developments and an informed future outlook.
- Detailed review of academic grants related to research on quantum computing in drug discovery, based on several relevant parameters, such as year of grants awarded, amount awarded, support period, type of study section, administering institute center, type of grant, activity code, funding mechanism and amount granted, funding institute and support period, prominent program officers (by number of grants), location of recipient organizations, popular recipient organizations, organization type and amount granted to popular recipient.
- An in-depth analysis of the various collaborations and partnerships that have been inked by stakeholders engaged in this domain, during the period 2017-2022. It includes a brief description of the partnership models adopted by stakeholders in this domain.
- A detailed use-case study on the applications of quantum computing across various industries, such as chemical industry, cybersecurity, financial modeling, space sciences, oil and gas industry and weather forecasting, and its likely evolution in the foreseen future.
- Information on five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of buyers, bargaining power of suppliers, threats of substitute product and rivalry among existing competitors.
- The detailed analysis of the current and future market based on blue ocean strategy, covering a strategic plan / guide for emerging players in this domain to help unlock an uncontested market, featuring thirteen strategic tools that can help software providers to shift towards a blue ocean strategic market.
- An insightful market forecast, highlighting the likely growth of quantum computing in drug discovery services market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented based on relevant parameters, such as drug discovery services offered (target identification / validation, hit generation / lead identification and lead optimization), type of therapeutic area (cardiovascular disorders, CNS disorders, dermatological disorders, endocrine disorders, gastrointestinal disorders, immunological disorders, infectious diseases, musculoskeletal disorders, oncological disorders, respiratory disorders and others), and key geographical regions ((North America (US and Canada), Europe (UK, France, Germany and Rest of the Europe), Asia-Pacific (China, Japan and Rest of the Asia Pacific), Latin America and Middle East and North Africa).
- Accenture
- Amazon Web Services
- Atos
- Fujitsu
- Huawei
- IBM
- Microsoft
- Xanadu
- XtalPi
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Quantum Computing in Drug Discovery
3.2. Drug Discovery and Development Timeline
3.3. Historical Evolution of Computational Drug Discovery Approaches
3.4. Classification of Quantum Computing Approaches
3.5. Applications of Quantum Computing in Drug Discovery Process
3.6. Advantages of Quantum Computing in Drug Discovery
3.7. Challenges Associated with Quantum Computing in Drug Discovery
3.8. Future Perspectives
4. MARKET LANDSCAPE: SOFTWARE PROVIDERS
4.1. Quantum Computing Software Providers: Overall Market Landscape
4.1.1. Analysis by Year of Establishment
4.1.2. Analysis by Company Size
4.1.3. Analysis by Location of Headquarters
4.1.4. Analysis by Business Capabilities
4.1.5. Analysis by Platform Capabilities
4.1.6. Analysis by Type of Drug Discovery Service(s) Offered
4.1.7. Analysis by Type of Molecule(s) Supported
4.1.8. Analysis by Compatible Computational Approaches
4.1.9. Analysis by End User(s)
4.1.10. Analysis by Therapeutic Area(s)
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Methodology and Key Parameters
5.2 Scoring Criteria
5.3. Company Competitiveness Analysis: Players based in North America (Peer Group I)
5.4. Company Competitiveness Analysis: Players based in Europe (Peer Group II)
5.5. Company Competitiveness Analysis: Players based in Asia-Pacific and Rest of the World (Peer Group III)
6. COMPANY PROFILES: SOFTWARE PROVIDERS
6.1. Accenture
6.1.1. Company Overview
6.1.2. Financial Information
6.1.3. Service Portfolio
6.1.4. Recent Developments and Future Outlook
6.2. Atos
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. Fujitsu
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Service Portfolio
6.3.4. Recent Developments and Future Outlook
6.4. Huawei
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Service Portfolio
6.4.4. Recent Developments and Future Outlook
6.5. Microsoft
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Service Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. Xanadu
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. XtalPi
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Recent Developments and Future Outlook
7. MARKET LANDSCAPE: HARDWARE PROVIDERS
7.1. Quantum Computing Hardware Providers: Overall Market Landscape
7.1.1. Analysis by Year of Establishment
7.1.2. Analysis by Company Size
7.1.3. Analysis by Region of Headquarters
7.1.4. Analysis by Location of Headquarters
7.1.5. Analysis by Type of Offering(s)
7.1.6. Analysis by Data Storage on Cloud
7.1.7. Analysis by Compatible Computational Approaches
7.1.8. Analysis by Type of Offering(s) and Compatible Computational Approaches
8. COMPANY PROFILES: HARDWARE PROVIDERS
8.1. Amazon Web Services
8.1.1. Company Overview
8.1.2. Financial Information
8.1.3. Service Portfolio
8.1.4. Recent Developments and Future Outlook
8.2. IBM
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. Microsoft
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook
9. ACADEMIC GRANTS ANALYSIS
9.1. Analysis Methodology
9.2. Key Parameters
9.3. Analysis by Year of Grant
9.4. Analysis by Amount Awarded
9.5. Analysis by Support Period
9.6. Analysis by Study Section
9.7. Word Cloud Analysis: Emerging Focus Areas
9.8. Analysis by Administering Institute Center
9.9. Analysis by Type of Grant
9.10. Analysis by Activity Code
9.11. Analysis by Purpose of Grant
9.12. Analysis by Administering Institute Center and Support Period
9.13. Prominent Program Officers: Analysis by Number of Grants
9.14. Analysis by Location of Recipient Organizations
9.15. Analysis by Type of Organization
9.16. Popular Recipient Organizations: Analysis by Number of Grants
9.17. Popular Recipient Organizations: Analysis by Amount Awarded
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Partnership Models
10.2. Quantum Computing in Drug Discovery, Drug Manufacturing and Other Services: Partnerships and Collaborations
10.3. Analysis by Year of Partnership
10.4. Analysis by Type of Partnership
10.5. Analysis by Year and Type of Partnership
10.6. Most Active Players: Analysis by Number of Partnerships
10.7. Word Cloud Analysis: Key Focus Areas
10.8. Analysis by Type of Continent
10.9. Analysis by Company Size and Type of Partnership
10.10. Local and Intercontinental Agreements
10.11. Intercontinental and Intracontinental Agreements
11. USE CASE STUDY
11.1. Overview of Quantum Computing
11.2. Applications of Quantum Computing Across Various Industries
11.3. Upcoming Trends in Quantum Computing
11.4. Future Perspectives
12. PORTER’S FIVE FORCES ANALYSIS
12.1. Methodology and Assumptions
12.2. Key Parameters
12.2.1. Threats of New Entrants
12.2.2. Bargaining Power of Buyers
12.2.3. Bargaining Power of Suppliers
12.2.4. Threats of Substitute Products
12.2.5. Rivalry among Existing Competitors
13. BLUE OCEAN STRATEGY: A STRATEGIC GUIDE FOR START-UPS TO ENTER INTO HIGHLY COMPETITIVE MARKET
13.1. Overview of Blue Ocean Strategy
13.1.1 Red Oceans
13.1.2 Blue Oceans
13.1.3 Comparison of Red Ocean Strategy and Blue Ocean Strategy
13.1.4. Quantum Computing in Drug Discovery Services Market: Blue Ocean Strategy and Shift Tools
13.1.4.1. Value Innovation
13.1.4.2. Strategy Canvas
13.1.4.3. Four Action Framework
13.1.4.4. Eliminate-Raise-Reduce-Create (ERRC) Grid
13.1.4.5. Six Path Framework
13.1.4.6. Pioneer-Migrator-Settler (PMS) Map
13.1.4.7. Three Tiers of Non-customers
13.1.4.8. Sequence of Blue Ocean Strategy
13.1.4.9. Buyer Utility Map
13.1.4.10. The Price Corridor of the Mass
13.1.4.11. Four Hurdles to Strategy Execution
13.1.4.12. Tipping Point Leadership
13.1.4.13. Fair Process
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Forecast Methodology and Key Assumptions
14.2. Quantum Computing in Drug Discovery Services Market, 2023-2035
14.2.1. Quantum Computing in Drug Discovery Services Market, 2023-2035: Analysis by Type of Drug Discovery Service Offered
14.2.1.1. Quantum Computing in Drug Discovery Services Market for Target Identification / Validation, 2023-2035
14.2.1.2. Quantum Computing in Drug Discovery Services Market for Hit Generation / Lead Identification, 2023-2035
14.2.1.3. Quantum Computing in Drug Discovery Services Market for Target Lead Optimization, 2023-2035
14.2.2. Quantum Computing in Drug Discovery Services Market, 2023-2035: Analysis by Therapeutic Area
14.2.2.1. Quantum Computing in Drug Discovery Services Market for Cardiovascular Disorders, 2023-2035
14.2.2.2. Quantum Computing in Drug Discovery Services Market for CNS Disorders, 2023-2035
14.2.2.3. Quantum Computing in Drug Discovery Services Market for Dermatological Disorders, 2023-2035
14.2.2.4. Quantum Computing in Drug Discovery Services Market for Endocrine Disorders, 2023-2035
14.2.2.5. Quantum Computing in Drug Discovery Services Market for Gastrointestinal Disorders, 2023-2035
14.2.2.6. Quantum Computing in Drug Discovery Services Market for Immunological Disorders, 2023-2035
14.2.2.7. Quantum Computing in Drug Discovery Services Market for Infectious Diseases, 2023-2035
14.2.2.8. Quantum Computing in Drug Discovery Services Market for Musculoskeletal Disorders, 2023-2035
14.2.2.9. Quantum Computing in Drug Discovery Services Market for Oncological Disorders, 2023-2035
14.2.2.10. Quantum Computing in Drug Discovery Services Market for Respiratory Disorders, 2023-2035
14.2.2.11. Quantum Computing in Drug Discovery Services Market for Others, 2023-2035
14.2.3. Quantum Computing in Drug Discovery Services Market, 2023-2035: Analysis by Key Geographical Regions
14.2.3.1. Quantum Computing in Drug Discovery Services Market in North America, 2023-2035
14.2.3.1.1. Quantum Computing in Drug Discovery Services Market in the US, 2023-2035
14.2.3.1.2. Quantum Computing in Drug Discovery Services Market in Canada, 2023-2035
14.2.3.2. Quantum Computing in Drug Discovery Services Market for Europe, 2023-2035
14.2.3.2.1. Quantum Computing in Drug Discovery Services Market in the UK, 2023-2035
14.2.3.2.2. Quantum Computing in Drug Discovery Services Market in France, 2023-2035
14.2.3.1.3. Quantum Computing in Drug Discovery Services Market in Germany, 2023-2035
14.2.3.1.4. Quantum Computing in Drug Discovery Services Market in Rest of the Europe, 2023-2035
14.2.3.3. Quantum Computing in Drug Discovery Services Market in Asia-Pacific, 2023-2035
14.2.3.3.1. Quantum Computing in Drug Discovery Services Market in China, 2023-2035
14.2.3.3.2. Quantum Computing in Drug Discovery Services Market in Japan, 2023-2035
14.2.3.3.3. Quantum Computing in Drug Discovery Services Market in Rest of Asia-Pacific, 2023-2035
14.2.3.4. Quantum Computing in Drug Discovery Services Market in Latin America, 2023-2035
14.2.3.5. Quantum Computing in Drug Discovery Services Market in Middle East and North Africa, 2023-2035
15. EXECUTIVE INSIGHTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Quantum Computing in Drug Discovery
3.2. Drug Discovery and Development Timeline
3.3. Historical Evolution of Computational Drug Discovery Approaches
3.4. Classification of Quantum Computing Approaches
3.5. Applications of Quantum Computing in Drug Discovery Process
3.6. Advantages of Quantum Computing in Drug Discovery
3.7. Challenges Associated with Quantum Computing in Drug Discovery
3.8. Future Perspectives
4. MARKET LANDSCAPE: SOFTWARE PROVIDERS
4.1. Quantum Computing Software Providers: Overall Market Landscape
4.1.1. Analysis by Year of Establishment
4.1.2. Analysis by Company Size
4.1.3. Analysis by Location of Headquarters
4.1.4. Analysis by Business Capabilities
4.1.5. Analysis by Platform Capabilities
4.1.6. Analysis by Type of Drug Discovery Service(s) Offered
4.1.7. Analysis by Type of Molecule(s) Supported
4.1.8. Analysis by Compatible Computational Approaches
4.1.9. Analysis by End User(s)
4.1.10. Analysis by Therapeutic Area(s)
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Methodology and Key Parameters
5.2 Scoring Criteria
5.3. Company Competitiveness Analysis: Players based in North America (Peer Group I)
5.4. Company Competitiveness Analysis: Players based in Europe (Peer Group II)
5.5. Company Competitiveness Analysis: Players based in Asia-Pacific and Rest of the World (Peer Group III)
6. COMPANY PROFILES: SOFTWARE PROVIDERS
6.1. Accenture
6.1.1. Company Overview
6.1.2. Financial Information
6.1.3. Service Portfolio
6.1.4. Recent Developments and Future Outlook
6.2. Atos
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. Fujitsu
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Service Portfolio
6.3.4. Recent Developments and Future Outlook
6.4. Huawei
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Service Portfolio
6.4.4. Recent Developments and Future Outlook
6.5. Microsoft
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Service Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. Xanadu
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. XtalPi
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Recent Developments and Future Outlook
7. MARKET LANDSCAPE: HARDWARE PROVIDERS
7.1. Quantum Computing Hardware Providers: Overall Market Landscape
7.1.1. Analysis by Year of Establishment
7.1.2. Analysis by Company Size
7.1.3. Analysis by Region of Headquarters
7.1.4. Analysis by Location of Headquarters
7.1.5. Analysis by Type of Offering(s)
7.1.6. Analysis by Data Storage on Cloud
7.1.7. Analysis by Compatible Computational Approaches
7.1.8. Analysis by Type of Offering(s) and Compatible Computational Approaches
8. COMPANY PROFILES: HARDWARE PROVIDERS
8.1. Amazon Web Services
8.1.1. Company Overview
8.1.2. Financial Information
8.1.3. Service Portfolio
8.1.4. Recent Developments and Future Outlook
8.2. IBM
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. Microsoft
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook
9. ACADEMIC GRANTS ANALYSIS
9.1. Analysis Methodology
9.2. Key Parameters
9.3. Analysis by Year of Grant
9.4. Analysis by Amount Awarded
9.5. Analysis by Support Period
9.6. Analysis by Study Section
9.7. Word Cloud Analysis: Emerging Focus Areas
9.8. Analysis by Administering Institute Center
9.9. Analysis by Type of Grant
9.10. Analysis by Activity Code
9.11. Analysis by Purpose of Grant
9.12. Analysis by Administering Institute Center and Support Period
9.13. Prominent Program Officers: Analysis by Number of Grants
9.14. Analysis by Location of Recipient Organizations
9.15. Analysis by Type of Organization
9.16. Popular Recipient Organizations: Analysis by Number of Grants
9.17. Popular Recipient Organizations: Analysis by Amount Awarded
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Partnership Models
10.2. Quantum Computing in Drug Discovery, Drug Manufacturing and Other Services: Partnerships and Collaborations
10.3. Analysis by Year of Partnership
10.4. Analysis by Type of Partnership
10.5. Analysis by Year and Type of Partnership
10.6. Most Active Players: Analysis by Number of Partnerships
10.7. Word Cloud Analysis: Key Focus Areas
10.8. Analysis by Type of Continent
10.9. Analysis by Company Size and Type of Partnership
10.10. Local and Intercontinental Agreements
10.11. Intercontinental and Intracontinental Agreements
11. USE CASE STUDY
11.1. Overview of Quantum Computing
11.2. Applications of Quantum Computing Across Various Industries
11.3. Upcoming Trends in Quantum Computing
11.4. Future Perspectives
12. PORTER’S FIVE FORCES ANALYSIS
12.1. Methodology and Assumptions
12.2. Key Parameters
12.2.1. Threats of New Entrants
12.2.2. Bargaining Power of Buyers
12.2.3. Bargaining Power of Suppliers
12.2.4. Threats of Substitute Products
12.2.5. Rivalry among Existing Competitors
13. BLUE OCEAN STRATEGY: A STRATEGIC GUIDE FOR START-UPS TO ENTER INTO HIGHLY COMPETITIVE MARKET
13.1. Overview of Blue Ocean Strategy
13.1.1 Red Oceans
13.1.2 Blue Oceans
13.1.3 Comparison of Red Ocean Strategy and Blue Ocean Strategy
13.1.4. Quantum Computing in Drug Discovery Services Market: Blue Ocean Strategy and Shift Tools
13.1.4.1. Value Innovation
13.1.4.2. Strategy Canvas
13.1.4.3. Four Action Framework
13.1.4.4. Eliminate-Raise-Reduce-Create (ERRC) Grid
13.1.4.5. Six Path Framework
13.1.4.6. Pioneer-Migrator-Settler (PMS) Map
13.1.4.7. Three Tiers of Non-customers
13.1.4.8. Sequence of Blue Ocean Strategy
13.1.4.9. Buyer Utility Map
13.1.4.10. The Price Corridor of the Mass
13.1.4.11. Four Hurdles to Strategy Execution
13.1.4.12. Tipping Point Leadership
13.1.4.13. Fair Process
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Forecast Methodology and Key Assumptions
14.2. Quantum Computing in Drug Discovery Services Market, 2023-2035
14.2.1. Quantum Computing in Drug Discovery Services Market, 2023-2035: Analysis by Type of Drug Discovery Service Offered
14.2.1.1. Quantum Computing in Drug Discovery Services Market for Target Identification / Validation, 2023-2035
14.2.1.2. Quantum Computing in Drug Discovery Services Market for Hit Generation / Lead Identification, 2023-2035
14.2.1.3. Quantum Computing in Drug Discovery Services Market for Target Lead Optimization, 2023-2035
14.2.2. Quantum Computing in Drug Discovery Services Market, 2023-2035: Analysis by Therapeutic Area
14.2.2.1. Quantum Computing in Drug Discovery Services Market for Cardiovascular Disorders, 2023-2035
14.2.2.2. Quantum Computing in Drug Discovery Services Market for CNS Disorders, 2023-2035
14.2.2.3. Quantum Computing in Drug Discovery Services Market for Dermatological Disorders, 2023-2035
14.2.2.4. Quantum Computing in Drug Discovery Services Market for Endocrine Disorders, 2023-2035
14.2.2.5. Quantum Computing in Drug Discovery Services Market for Gastrointestinal Disorders, 2023-2035
14.2.2.6. Quantum Computing in Drug Discovery Services Market for Immunological Disorders, 2023-2035
14.2.2.7. Quantum Computing in Drug Discovery Services Market for Infectious Diseases, 2023-2035
14.2.2.8. Quantum Computing in Drug Discovery Services Market for Musculoskeletal Disorders, 2023-2035
14.2.2.9. Quantum Computing in Drug Discovery Services Market for Oncological Disorders, 2023-2035
14.2.2.10. Quantum Computing in Drug Discovery Services Market for Respiratory Disorders, 2023-2035
14.2.2.11. Quantum Computing in Drug Discovery Services Market for Others, 2023-2035
14.2.3. Quantum Computing in Drug Discovery Services Market, 2023-2035: Analysis by Key Geographical Regions
14.2.3.1. Quantum Computing in Drug Discovery Services Market in North America, 2023-2035
14.2.3.1.1. Quantum Computing in Drug Discovery Services Market in the US, 2023-2035
14.2.3.1.2. Quantum Computing in Drug Discovery Services Market in Canada, 2023-2035
14.2.3.2. Quantum Computing in Drug Discovery Services Market for Europe, 2023-2035
14.2.3.2.1. Quantum Computing in Drug Discovery Services Market in the UK, 2023-2035
14.2.3.2.2. Quantum Computing in Drug Discovery Services Market in France, 2023-2035
14.2.3.1.3. Quantum Computing in Drug Discovery Services Market in Germany, 2023-2035
14.2.3.1.4. Quantum Computing in Drug Discovery Services Market in Rest of the Europe, 2023-2035
14.2.3.3. Quantum Computing in Drug Discovery Services Market in Asia-Pacific, 2023-2035
14.2.3.3.1. Quantum Computing in Drug Discovery Services Market in China, 2023-2035
14.2.3.3.2. Quantum Computing in Drug Discovery Services Market in Japan, 2023-2035
14.2.3.3.3. Quantum Computing in Drug Discovery Services Market in Rest of Asia-Pacific, 2023-2035
14.2.3.4. Quantum Computing in Drug Discovery Services Market in Latin America, 2023-2035
14.2.3.5. Quantum Computing in Drug Discovery Services Market in Middle East and North Africa, 2023-2035
15. EXECUTIVE INSIGHTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
